Macular Ganglion Cell Analysis (GCA) of the Cirrus HD-OCT in Glaucoma

To determine the area under the Receiver Operator Characteristic Curve (AUC) for the following GCA parameters:

• Minimum thickness
• Supero-temporal thickness
• Superior thickness
• Supero-nasal thickness
• Infero-temporal thickness
• Inferior thickness
• Infero-nasal thickness

Inclusion criteria

• Age of 40 years or older
• Diagnosed to have glaucoma by the Principal Investigator or co-investigator
• Able and willing to make the required study visits
• Able and willing to give consent and follow study instructions

Exclusion criteria

Ophthalmic:

• Best corrected visual acuity in either eye worse than 20/40 on a Snellen chart or on a Snellen equivalent acuity chart.
• Refractive error outside -12.00D to +8.00D spherical range or >-3.00D cylinder.
• Previous vitreoretinal surgery in study eye.
• Vitreoretinal traction or epiretinal membrane in the study eye.
• Any active infection of anterior or posterior segments.
• Evidence of diabetic retinopathy, diabetic macular edema, or other vitreoretinal disease in the study eye upon dilated examination, or upon evaluation of retinal photos.

Systemic:

• History of diabetes, leukemia, AIDS, uncontrolled systemic hypertension, dementia or multiple sclerosis.
• A life threatening or debilitating disease.
• Participation in any study involving a non-FDA approved investigational drug (IND) within the past month, or ongoing participation in a study with a non-FDA approved or cleared investigational device (IDE).
• Current or recent (within the past 14 days) use of an agent with photosensitizing properties by any route (e.g., Visudyne®, ciprofloxacin, Bactrim®, doxycycline, etc.).
• Concomitant use of hydrochloroquine and/or chloroquine.